A validation study of crescents in predicting ESRD in patients with IgA nephropathy

Table 2 Multivariate analysis of crescents with renal outcomes in IgAN patients with or without immunosuppression

Variable	All patients			With immunosuppression		Without immunosuppression
Variable	Events	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value
Primary outcome	144 (12.5)
C0 (n = 619)	80 (12.9)	Reference	/	Reference	/	Reference	/
C1 (n = 447)	46 (10.3)	1.07 (0.71–1.63)	0.74	0.76 (0.42–1.40)	0.38	1.05 (0.53–2.08)	0.89
C2 (n = 86)	18 (20.9)	0.84 (0.41–1.73)	0.63	1.09 (0.41–2.86)	0.87	0.48 (0.12–1.91)	0.30
C1 + C2 (n = 533)	64 (12.0)	1.02 (0.68–1.52)	0.93	0.85 (0.49–1.49)	0.58	0.88 (0.46–1.70)	0.71
Secondary outcome	162 (14.1)
C0 (n = 619)	89 (14.4)	Reference	/	Reference	/	Reference	/
C1 (n = 447)	54 (12.1)	1.01 (0.69–1.48)	0.97	0.80 (0.46–1.41)	0.44	0.88 (0.49–1.60)	0.68
C2 (n = 86)	19 (22.1)	0.77 (0.40–1.50)	0.44	1.16 (0.49–2.73)	0.74	0.32 (0.09–1.21)	0.09
C1 + C2 (n = 533)	73 (13.7)	0.93 (0.64–1.33)	0.68	0.86 (0.51–1.45)	0.57	0.72 (0.41–1.29)	0.27

HRs were adjusted for age, gender, initial eGFR, MAP, proteinuria, and Oxford classification indicators (including mesangial hypercellularity, endocapillary hypercellularity, segmental glomerulosclerosis and tubular atrophy/interstitial fibrosis)

ISSN: 1479-5876